We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.


Any AUS or NZ company


Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of PAR: rating 3
(3 out of 5)



Computershare, Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PAR5
Address: Level 2, 517 Flinders Lane, MELBOURNE, VIC, AUSTRALIA, 3000
Tel:  (03) 9629 5566 Fax: 

Date first listed: 19/08/2015
Company Secretary: Mr Kevin Hollingsworth
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ

News & Events

Expand this box to read and print

The suspension of trading in the securities of Paradigm Biopharmaceutics Limited will be lifted immediately, following the release by PAR of an announcement regarding the completion of a capital raising.


Bids received significantly exceeded the size of the placement. PAR fully funded to Phase 3 OA trial completion and readout. Support from large Australian and International institutional investors. Significant endorsement of PAR and its treatment of OA. Capital raising enables PAR to be focused on the clear path to regulatory approval and commercialisation.


The company releases a notice of Proposed issue of Securities - PAR.


The company will host a conference call at 8:30am (AEST) Wednesday 8th April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials. Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked. Questions are to be submitted to investorrelations@paradigmbiopharma.com.


Paradigm reports very encouraging real-world data ahead of its phase 3 OA clinical trial using the Phase 3 product and two Phase 3 endpoints.


The company receives clarity on US regulatory pathway. The pre-IND meeting was both positive and informative for Paradigm. The positive outcomes from the meeting were clear guidance around the primary and secondary endpoints for the Phase 3 clinical trial, the number of Phase 3 studies required for registration and overall clarity and guidance over the requirements for the Phase 3 clinical trial design and NDA submission.


The company releases its latest Corporate Presentation.


The securities of Paradigm Biopharmaceuticals Limited will be suspended from quotation immediately under Listing Rules 17.2, at the request of PAR, pending the release of an announcement regarding the proposed capital raising.


listed entity carried for record purposes only



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    11/05/2020John Gaffney-115,695$2.369$274,118
    13/03/2020Paul Rennie28,500$1.747$49,786
    13/11/2019Chris Fullerton100,000$3.011$301,045
    28/06/2019Paul Rennie35,000$1.400$49,000
    27/06/2019Chris Fullerton114,500$1.484$169,920

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Paul RennieNon Exec Chairman19/08/2015
    Jeannie JoughinCOO03/06/2020
    Justin CahillCFO13/10/2020
    Kevin HollingsworthCFO19/08/2015
    Amos MeltzerIndependent Director08/12/2020
    Helen FisherNon Exec Director11/02/2021
    John GaffneyNon Exec Director19/08/2015
    Donna SkerrettExecutive Director, Interim CEO03/07/2020

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Chris FullertonNon Exec Director19/08/201520/11/2020
    Graeme KaufmanNon Exec Chairman19/08/201524/06/2020

    Date of first appointment, title may have changed.